Vertex Pharmaceuticals announced Health Canada has granted Marketing Authorization for Casgevy, an autologous genome edited hematopoietic stem cell-based therapy, for the treatment of patients 12 years of age and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia. There are an estimated 2,000 patients eligible for Casgevy in Canada, the company said.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex treatment of myotonic dystrophy type 1 granted FDA orphan designation
- Shopify, Spotify added to ‘Signature Picks’ portfolio at Wells Fargo
- Eli Lilly named new top large pharma pick at Wells Fargo
- RMR Group announces early renewal of Vertex Pharmaceuticals lease
- Vertex Pharmaceuticals annoucnes Casgevy reimbursement agreement in England
Questions or Comments about the article? Write to editor@tipranks.com